Robert Vink is an Emeritus Professor at the University of South Australia and is currently Chair of the Board for Connectivity: Traumatic Brain Injury Australia. He was previously appointed as the Professor and Chair of Neurosurgical Research and Head of School, Medical Sciences at the University of Adelaide, Australia. Throughout his time as a teaching/research academic he led a highly productive research group and maintained an extensive publication output. He is the author of over 260 articles and book chapters. He has supervised more than 30 graduate research students, many of whom now hold significant academic and other positions throughout Australia and internationally.He is known internationally for his work in traumatic brain injury and has received numerous prestigious awards and appointments related to this. He currently provides research consulting services to universities and the pharmaceutical industry.

• 1. The synthesis, release, and binding of substance PBrendan A. Hilliard, Robert Vink, and Mary F. Barbe2. Distribution of substance P receptors in mammalsHonoo Satake, Akira Shiraishi, and Tsuyoshi Kawada3. Substance P in nonmammalian biology: Evolutionarily conserved tachykinin signalingDick R. Nassel4. Methodological foundations of substance P detectionNuray Erin5. Substance P receptor antagonistsFrancisco D. Rodrıguez and Rafael Covenas6. Substance P in the cardiovascular systemMagdalena Chottova Dvorakova and Shashank Pandey7. Substance P in lower urinary tract function and dysfunctionMitsuharu Yoshiyama8. Role of the substance P in learning and memoryNatalia Favila and Paul G. Overton9. Substance P in nausea and vomitingPaul L.R. Andrews, John A. Rudd, and Gareth J. Sanger10. Substance P in the central control of respirationNicholas J. Burgraff and Jan-Marino Ramirez11. Substance P in bone metabolismTanja Niedermair and Susanne Grassel12. Life without substance P: The naked mole ratAishi Zhao, Jiwon Lee, Weronika Gryszkiewicz, and Thomas J. Park13. Substance P in inflammationSophie E. Sipprell and Ian Marriott14. Substance P in oxidative stressSeyed Isaac Hashemy and Safieh Ebrahimi15. Substance P in painRobert Vink16. Substance P in cancerMiguel Munoz, Marisa Rosso, Riffat Mehboob, and Francisco Esteban17. Substance P in cardiac dysfunctionScott P. Levick and Alexander Widiapradja18. Substance P in neurotraumaRebecca George, Justin Krieg, and Frances Corrigan19. Substance P in strokeAnnabel Sorby-Adams20. Substance P in Alzheimer’s and Parkinson’s diseaseSeverini Cinzia21. Substance P receptor antagonists for major depressive disorderNadia M.J. Rupniak and Mark S. Kramer22 From a putative antidepressant to a validated mouse model of ADHD via NK1 receptorsS.C. Stanford23. Substance P in stress and anxietyKarl Ebner and Nicolas Singewald24. Substance P-neurokinin 1 receptor pathway in musculoskeletal disordersBrendan A. Hilliard and Mary F. Barbe25. Substance P and sudden infant death syndrome (SIDS)F. Bright, Robert Vink, and R.W. Byard26. Immunobiology and pharmacology of neuropeptide substance PEhsan Aslam, Asina Gijasi, Caroline Perner, Rob van Wijk, Anne-Grete Martson, Gerard J.P. van Westen, Ilze Bot, Laura H. Heitman, and Alireza Mashaghi27. Substance P in viral diseases—Especially coronavirus diseaseRiffat Mehboob, Mariam Hashim, and Miguel Munoz28. Substance P: Perspectives and future directionsRobert Vink

Robert Vink is an Emeritus Professor at the University of South Australia and is currently Chair of the Board for Connectivity: Traumatic Brain Injury Australia. He was previously appointed as the Professor and Chair of Neurosurgical Research and Head of School, Medical Sciences at the University of Adelaide, Australia. Throughout his time as a teaching/research academic he led a highly productive research group and maintained an extensive publication output. He is the author of over 260 articles and book chapters. He has supervised more than 30 graduate research students, many of whom now hold significant academic and other positions throughout Australia and internationally.He is known internationally for his work in traumatic brain injury and has received numerous prestigious awards and appointments related to this. He currently provides research consulting services to universities and the pharmaceutical industry.

• 1. The synthesis, release, and binding of substance PBrendan A. Hilliard, Robert Vink, and Mary F. Barbe2. Distribution of substance P receptors in mammalsHonoo Satake, Akira Shiraishi, and Tsuyoshi Kawada3. Substance P in nonmammalian biology: Evolutionarily conserved tachykinin signalingDick R. Nassel4. Methodological foundations of substance P detectionNuray Erin5. Substance P receptor antagonistsFrancisco D. Rodrıguez and Rafael Covenas6. Substance P in the cardiovascular systemMagdalena Chottova Dvorakova and Shashank Pandey7. Substance P in lower urinary tract function and dysfunctionMitsuharu Yoshiyama8. Role of the substance P in learning and memoryNatalia Favila and Paul G. Overton9. Substance P in nausea and vomitingPaul L.R. Andrews, John A. Rudd, and Gareth J. Sanger10. Substance P in the central control of respirationNicholas J. Burgraff and Jan-Marino Ramirez11. Substance P in bone metabolismTanja Niedermair and Susanne Grassel12. Life without substance P: The naked mole ratAishi Zhao, Jiwon Lee, Weronika Gryszkiewicz, and Thomas J. Park13. Substance P in inflammationSophie E. Sipprell and Ian Marriott14. Substance P in oxidative stressSeyed Isaac Hashemy and Safieh Ebrahimi15. Substance P in painRobert Vink16. Substance P in cancerMiguel Munoz, Marisa Rosso, Riffat Mehboob, and Francisco Esteban17. Substance P in cardiac dysfunctionScott P. Levick and Alexander Widiapradja18. Substance P in neurotraumaRebecca George, Justin Krieg, and Frances Corrigan19. Substance P in strokeAnnabel Sorby-Adams20. Substance P in Alzheimer’s and Parkinson’s diseaseSeverini Cinzia21. Substance P receptor antagonists for major depressive disorderNadia M.J. Rupniak and Mark S. Kramer22 From a putative antidepressant to a validated mouse model of ADHD via NK1 receptorsS.C. Stanford23. Substance P in stress and anxietyKarl Ebner and Nicolas Singewald24. Substance P-neurokinin 1 receptor pathway in musculoskeletal disordersBrendan A. Hilliard and Mary F. Barbe25. Substance P and sudden infant death syndrome (SIDS)F. Bright, Robert Vink, and R.W. Byard26. Immunobiology and pharmacology of neuropeptide substance PEhsan Aslam, Asina Gijasi, Caroline Perner, Rob van Wijk, Anne-Grete Martson, Gerard J.P. van Westen, Ilze Bot, Laura H. Heitman, and Alireza Mashaghi27. Substance P in viral diseases—Especially coronavirus diseaseRiffat Mehboob, Mariam Hashim, and Miguel Munoz28. Substance P: Perspectives and future directionsRobert Vink

Robert Vink is an Emeritus Professor at the University of South Australia and is currently Chair of the Board for Connectivity: Traumatic Brain Injury Australia. He was previously appointed as the Professor and Chair of Neurosurgical Research and Head of School, Medical Sciences at the University of Adelaide, Australia. Throughout his time as a teaching/research academic he led a highly productive research group and maintained an extensive publication output. He is the author of over 260 articles and book chapters. He has supervised more than 30 graduate research students, many of whom now hold significant academic and other positions throughout Australia and internationally.He is known internationally for his work in traumatic brain injury and has received numerous prestigious awards and appointments related to this. He currently provides research consulting services to universities and the pharmaceutical industry.

• 1. The synthesis, release, and binding of substance PBrendan A. Hilliard, Robert Vink, and Mary F. Barbe2. Distribution of substance P receptors in mammalsHonoo Satake, Akira Shiraishi, and Tsuyoshi Kawada3. Substance P in nonmammalian biology: Evolutionarily conserved tachykinin signalingDick R. Nassel4. Methodological foundations of substance P detectionNuray Erin5. Substance P receptor antagonistsFrancisco D. Rodrıguez and Rafael Covenas6. Substance P in the cardiovascular systemMagdalena Chottova Dvorakova and Shashank Pandey7. Substance P in lower urinary tract function and dysfunctionMitsuharu Yoshiyama8. Role of the substance P in learning and memoryNatalia Favila and Paul G. Overton9. Substance P in nausea and vomitingPaul L.R. Andrews, John A. Rudd, and Gareth J. Sanger10. Substance P in the central control of respirationNicholas J. Burgraff and Jan-Marino Ramirez11. Substance P in bone metabolismTanja Niedermair and Susanne Grassel12. Life without substance P: The naked mole ratAishi Zhao, Jiwon Lee, Weronika Gryszkiewicz, and Thomas J. Park13. Substance P in inflammationSophie E. Sipprell and Ian Marriott14. Substance P in oxidative stressSeyed Isaac Hashemy and Safieh Ebrahimi15. Substance P in painRobert Vink16. Substance P in cancerMiguel Munoz, Marisa Rosso, Riffat Mehboob, and Francisco Esteban17. Substance P in cardiac dysfunctionScott P. Levick and Alexander Widiapradja18. Substance P in neurotraumaRebecca George, Justin Krieg, and Frances Corrigan19. Substance P in strokeAnnabel Sorby-Adams20. Substance P in Alzheimer’s and Parkinson’s diseaseSeverini Cinzia21. Substance P receptor antagonists for major depressive disorderNadia M.J. Rupniak and Mark S. Kramer22 From a putative antidepressant to a validated mouse model of ADHD via NK1 receptorsS.C. Stanford23. Substance P in stress and anxietyKarl Ebner and Nicolas Singewald24. Substance P-neurokinin 1 receptor pathway in musculoskeletal disordersBrendan A. Hilliard and Mary F. Barbe25. Substance P and sudden infant death syndrome (SIDS)F. Bright, Robert Vink, and R.W. Byard26. Immunobiology and pharmacology of neuropeptide substance PEhsan Aslam, Asina Gijasi, Caroline Perner, Rob van Wijk, Anne-Grete Martson, Gerard J.P. van Westen, Ilze Bot, Laura H. Heitman, and Alireza Mashaghi27. Substance P in viral diseases—Especially coronavirus diseaseRiffat Mehboob, Mariam Hashim, and Miguel Munoz28. Substance P: Perspectives and future directionsRobert Vink